The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
News|Videos|June 23, 2025 (Updated: September 10, 2025)
DAREONTM-9, a Phase 1b Study of Obrixtamig Plus Topotecan in Patients (Pts) With Advanced Small Cell Lung Cancer (SCLC): Interim Analysis Results
Author(s)Martin Dietrich, MD, PhD
Martin Dietrich, MD, live from the 2025 ASCO Annual Meeting, presents interim results from the phase 1b DAREONTM-9 study, showing that obrixtamig combined with topotecan is well tolerated and demonstrates promising preliminary efficacy in patients with relapsed or refractory small cell lung cancer, with a confirmed overall response rate of 69%.
Advertisement
Advertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5